Alternative Name: SCHIELD Biodegradable MPT Implant
Description: The SCHIELD implant will be designed for sustained, long-acting delivery of API, capable of dual indication (anti-retroviral plus contraceptive) with zero-order release kinetics. This biodegradable, reversible implant will be subcutaneously placed, discrete, and user-independent to eliminate patient burden.
Delivery Method: Subdermal
Duration Type: Long-acting
Duration: 12-18 months
- single subcutaneous injection every 12 months
Inactive material: Polycaprolactone; GRAS excipient
Multipurpose Preventive Technology (MPT): Yes
Project Phase: Pre-Clinical and Clinical Development
Development Stage: Pre-clinical
Began discovery in: 17-Jul
Active Development: Yes
- This product is still in the early development phase. The API screening and formulations are currently underway, as well as implant fabrication and prototyping.